文献速递泌尿男性生殖肿瘤

美国退伍军人健康管理局机构内前列腺特异性抗原筛查率与后续转移性前列腺癌发病率的相关性

Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
PubMed 文献 · JAMA Oncol · 2022-01-01

该回顾性队列纳入美国退伍军人健康管理局128家机构40岁及以上男性,分析2005年至2019年机构水平PSA筛查率与5年后转移性前列腺癌发病率的关系。PSA筛查率从2005年47.2%降至2019年37.0%,转移性前列腺癌发病率从5.2/10万升至7.9/10万。机构PSA筛查率每增加10%,5年后转移性前列腺癌发病率降低(IRR 0.91,95%CI 0.87-0.96,P<.001)。

要点

  • 2005年至2019年,美国退伍军人健康管理局系统PSA筛查率从47.2%降至37.0%。
  • 同期转移性前列腺癌发病率从5.2/10万升至7.9/10万。
  • 机构PSA筛查率每增加10%,5年后转移性前列腺癌发病率IRR为0.91(95%CI 0.87-0.96,P<.001)。

核心结论

  • 2005年至2019年美国退伍军人健康管理局系统PSA筛查率下降,PSA筛查率较高的机构后续转移性前列腺癌发病率较低。
  • 这些数据可用于为希望降低转移性前列腺癌风险的男性进行PSA筛查潜在获益的共同决策提供信息。

研究设计与样本

  • 回顾性队列研究,使用2005年1月1日至2019年12月31日美国退伍军人健康管理局128家机构40岁及以上男性的数据。
  • 2005年队列包括4 678 412名男性,2019年包括5 371 701名男性。
  • 暴露为2005年1月1日至2014年12月31日每年的机构水平PSA筛查率(40岁及以上男性中每年接受PSA检测的比例)和长期未筛查率(40岁及以上男性中过去3年未接受PSA检测的比例)。
  • 主要结局为每个PSA筛查暴露年5年后机构水平每年新发转移性前列腺癌诊断计数和年龄调整的每年转移性前列腺癌发病率(每10万男性)。

主要发现

  • PSA筛查率从2005年47.2%降至2019年37.0%。
  • 转移性前列腺癌发病率从2005年5.2/10万升至2019年7.9/10万。
  • 机构水平PSA筛查率较高与5年后转移性前列腺癌发病率较低相关(PSA筛查率每增加10%,IRR 0.91;95%CI 0.87-0.96;P<.001)。
  • 长期未筛查率较高与5年后转移性前列腺癌发病率较高相关(长期未筛查率每增加10%,IRR 1.11;95%CI 1.03-1.19;P=.01)。

临床怎么用

  • 作者指出这些数据可用于为希望降低转移性前列腺癌风险的男性进行PSA筛查潜在获益的共同决策提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is controversy about the benefit of prostate-specific antigen (PSA) screening. Prostate-specific antigen screening rates have decreased since 2008 in the US, and the incidence of metastatic prostate cancer has increased. However, there is no direct epidemiologic evidence of a correlation between population PSA screening rates and subsequent metastatic prostate cancer rates. OBJECTIVE: To assess whether facility-level variation in PSA screening rates is associated with subsequent facility-level metastatic prostate cancer incidence. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort used data for all men aged 40 years or older with an encounter at 128 facilities in the US Veterans Health Administration (VHA) from January 1, 2005, to December 31, 2019. EXPOSURES: Yearly facility-level PSA screening rates, defined as the proportion of men aged 40 years or older with a PSA test in each year, and long-term nonscreening rates, defined as the proportion of men aged 40 years or older without a PSA test in the prior 3 years, from January 1, 2005, to December 31, 2014. MAIN OUTCOMES AND MEASURES: The main outcomes were facility-level yearly counts of incident metastatic prostate cancer diagnoses and age-adjusted yearly metastatic prostate cancer incidence rates (per 100 000 men) 5 years after each PSA screening exposure year. RESULTS: The cohort included 4 678 412 men in 2005 and 5 371 701 men in 2019. Prostate-specific antigen screening rates decreased from 47.2% in 2005 to 37.0% in 2019, and metastatic prostate cancer incidence increased from 5.2 per 100 000 men in 2005 to 7.9 per 100 000 men in 2019. Higher facility-level PSA screening rates were associated with lower metastatic prostate cancer incidence 5 years later (incidence rate ratio [IRR], 0.91 per 10% increase in PSA screening rate; 95% CI, 0.87-0.96; P < .001). Higher long-term nonscreening rates were associated with higher metastatic prostate cancer incidence 5 years later (IRR, 1.11 per 10% increase in long-term nonscreening rate; 95% CI, 1.03-1.19; P = .01). CONCLUSIONS AND RELEVANCE: From 2005 to 2019, PSA screening rates decreased in the national VHA system. Facilities with higher PSA screening rates had lower subsequent rates of metastatic prostate cancer. These data may be used to inform shared decision-making about the potential benefits of PSA screening among men who wish to reduce their risk of metastatic prostate cancer.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Bryant AK, Lee KM, Alba PR, et al. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities. JAMA Oncol. 2022. PMID: 36279204. doi:10.1001/jamaoncol.2022.4319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。